| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Propargyl-PEG1-NHS ester does not have a specific biological target. It is a chemical linker used in bioconjugation. The NHS ester reacts with primary amines on proteins, peptides, or other molecules, while the alkyne group enables click chemistry conjugation.
|
|---|---|
| ln Vitro |
In vitro, Propargyl-PEG1-NHS ester is used as a reagent in chemical synthesis to create conjugates, such as antibody-drug conjugates (ADCs). It is not a drug itself but a tool for drug development. Its activity is defined by its chemical reactivity.
|
| ln Vivo |
In vivo, Propargyl-PEG1-NHS ester is not used as a therapeutic agent. It is used in the synthesis of ADCs, which are then tested in vivo. The linker itself is not the active drug.
|
| Enzyme Assay |
Cell-free assays for Propargyl-PEG1-NHS ester are not relevant, as it is a chemical reagent. Its properties are characterized by its chemical purity and reactivity, which can be assessed using analytical techniques like NMR and HPLC.
|
| Cell Assay |
In vitro cell-based assays are not typically performed for Propargyl-PEG1-NHS ester itself. However, it can be used to synthesize ADCs or other conjugates that are then tested in cell-based assays.
|
| Animal Protocol |
In vivo animal experiments are not performed for Propargyl-PEG1-NHS ester itself. It is used as a building block to synthesize ADCs, which are then tested in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for Propargyl-PEG1-NHS ester is not available, as it is a chemical linker not intended for therapeutic use. Its properties are determined by its chemical structure.
|
| Toxicity/Toxicokinetics |
Toxicological data for Propargyl-PEG1-NHS ester is not available. As a research chemical, it should be handled with care. Its use is strictly for research purposes.
|
| Additional Infomation |
Propargyl-PEG1-NHS ester is a research-grade heterobifunctional linker used in bioconjugation and ADC synthesis. It contains an NHS ester for amine conjugation and an alkyne for click chemistry. It has not been approved for clinical use. All information is for research reference only.
|
| Molecular Formula |
C10H11NO5
|
|---|---|
| Molecular Weight |
225.19800
|
| Exact Mass |
225.064
|
| CAS # |
1174157-65-3
|
| PubChem CID |
51340986
|
| Appearance |
Colorless to light yellow liquid
|
| Melting Point |
36-41°C
|
| LogP |
-0.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
16
|
| Complexity |
338
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(ON1C(CCC1=O)=O)CCOCC#C
|
| InChi Key |
WKIKHHMUNOVQLD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H11NO5/c1-2-6-15-7-5-10(14)16-11-8(12)3-4-9(11)13/h1H,3-7H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-prop-2-ynoxypropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~444.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 2.5 mg/mL (11.10 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4405 mL | 22.2025 mL | 44.4050 mL | |
| 5 mM | 0.8881 mL | 4.4405 mL | 8.8810 mL | |
| 10 mM | 0.4440 mL | 2.2202 mL | 4.4405 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.